Skip to main content
. 2013 May 31;11:135. doi: 10.1186/1479-5876-11-135

Table 3.

Clinical response in 17 evaluable patients

  No. (%) Clinical benefit Median OS (months)
PR
1 (5.8)
7/17 (41%)
14
SD
6 (35.2)
PD
10 (58.8)
 
6.5
All 17 patients     10

PR Partial response, SD Stable disease, PD Progressive disease, OS Overall survival.